CoChat

Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies

Open access
Zhou, Jing, Ji, Qing, Li, Qi · 2021 · Journal of Experimental & Clinical Cancer Research

The DOI matches its Crossref record; 156 of the 156 references it cites were found in a registry or an index; 37 of the 185 sources its claims cite were checked for support.

Abstract

Cetuximab and panitumumab are monoclonal antibodies (mAbs) against epidermal growth factor receptor (EGFR) that are effective agents for metastatic colorectal cancer (mCRC). Cetuximab can prolong survival by 8.2 months in RAS wild-type (WT) mCRC patients. Unfortunately, resistance to targeted therapy impairs clinical use and efficiency. The mechanisms of resistance refer to intrinsic and extrinsic alterations of tumours. Multiple therapeutic strategies have been investigated extensively to overcome resistance to anti-EGFR mAbs. The intrinsic mechanisms include EGFR ligand overexpression, EGFR alteration,RAS/RAF/PI3K gene mutations, ERBB2/MET/IGF-1R activation, metabolic remodelling, microsatellite instability and autophagy. For intrinsic mechanisms, therapies mainly cover the following: new EGFR-targeted inhibitors, a combination of multitargeted inhibitors, and metabolic regulators. In addition, new cytotoxic drugs and small molecule compounds increase the efficiency of cetuximab. Extrinsic alterations mainly disrupt the tumour microenvironment, specifically immune cells, cancer-associated fibroblasts (CAFs) and angiogenesis. The directions include the modification or activation of immune cells and suppression of CAFs and anti-VEGFR agents. In this review, we focus on the mechanisms of resistance to anti-EGFR monoclonal antibodies (anti-EGFR mAbs) and discuss diverse approaches to reverse resistance to this therapy in hopes of identifying more mCRC treatment possibilities.

Overview

CoChat Summary

TL;DR

This review summarizes intrinsic and extrinsic mechanisms of resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer and discusses preclinical and clinical strategies to reverse that resistance. It emphasizes that resistance is driven by genetic alterations, compensatory signaling, metabolic remodeling, immune microenvironment changes, CAFs, and angiogenesis, with combination and multitargeted approaches showing the most promise.

Key findings

  • Anti-EGFR mAbs benefit only a subset of mCRC patients: cetuximab plus FOLFIRI reduced progression risk by 15% and increased OS by 8.2 months in KRAS WT mCRC versus FOLFIRI alone, but clinical benefit in responders lasts only 8–10 months, and approximately 80% of responders develop resistance.
  • Intrinsic resistance mechanisms include EGFR ligand overexpression, EGFR extracellular domain mutations (e.g., G465R, G465E, S468R, S492R), RAS/RAF/PI3K pathway mutations, ERBB2/MET/IGF-1R activation, metabolic remodeling, microsatellite instability, autophagy, CSCs, and EMT.
  • Reversal strategies include new anti-EGFR antibodies (necitumumab, Sym004, GC1118, MM-151), multitargeted inhibitors, metabolic regulators, immune therapies, CAF suppression, and antiangiogenic agents. Notable reported results include encorafenib + binimetinib + cetuximab in BRAF V600E mCRC (ORR 26% vs 2%; mOS 9.0 vs 5.4 months), capmatinib + gefitinib in MET-amplified disease (ORR 47%), and tivantinib + cetuximab (ORR 9.8%, mPFS 2.6 months, mOS 9.2 months).
  • Extrinsic resistance involves impaired ADCC, dysfunctional NK/T cells, CAF-secreted growth factors, and angiogenesis; avelumab + cetuximab in RAS WT acquired resistance gave mPFS 3.6 months and mOS 11.6 months, while regorafenib + cetuximab produced partial response in 1/17 and stable disease in 7/17 patients.

Methods

  • Narrative review of published literature on mechanisms of resistance to anti-EGFR mAbs in mCRC and strategies to reverse resistance.
  • Synthesizes preclinical and clinical evidence, including two summary tables: Table 1 for clinical trials and Table 2 for preclinical studies.
  • No primary experimental data, systematic search strategy, or meta-analysis is described.

Limitations

  • The paper does not state formal limitations.
  • Evident from the text: as a review, it provides no new primary data, and conclusions depend on cited studies that include small, early-phase, case-report, and preclinical evidence.
  • Evident from the text: several strategies show conflicting or negative results (e.g., vemurafenib studies, PX-866 plus cetuximab, selumetinib plus cetuximab, dalotuzumab/IMC-A12), and the paper notes that more clinical studies are needed for MEK inhibitors, new anti-EGFR mAbs, and cytotoxic agents before clinical application.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/s13046-021-02130-2

Cites

156 of 156 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Intrinsic mechanisms of resistance to anti-EGFR mAbs in metastatic colorectal cancer. The intrinsic mechanisms include abnormal activation of oncogenic signalling pathways, aberrant gene expression, metabolic disorders, increased autophagy function and cancer stem cells. For example, genomic alterations and proteic phosphorylation induce activation of the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR cascades. ERBB2/MET amplification and abnormal IGF-1R activation stimulate compensatory feedback loop signalling of EGFR. The phenotype shift of cancer stem cells (CSCs) into epithelial-to-mesenchymal transition (EMT) contributes to therapy resistance. Glycolysis, lipid synthesis, fatty acid oxidation and vitamin deficiency in cancer cells also reduced the efficiency of EGFR-targeted therapy. The agents for specific points are also shown in the figure. Abbreviations: CSC, cancer stem cell; EMT, epithelial-to-mesenchymal transition; PI3K, phosphoinositide 3-kinase; IGF-1R, insulin-like growth Factor 1 receptor
Fig. 1 Intrinsic mechanisms of resistance to anti-EGFR mAbs in metastatic colorectal cancer. The intrinsic mechanisms include abnormal activation of oncogenic signalling pathways, aberrant gene expression, metabolic disorders, increased autophagy function and cancer stem cells. For example, genomic alterations and proteic phosphorylation induce activation of the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR cascades. ERBB2/MET amplification and abnormal IGF-1R activation stimulate compensatory feedback loop signalling of EGFR. The phenotype shift of cancer stem cells (CSCs) into epithelial-to-mesenchymal transition (EMT) contributes to therapy resistance. Glycolysis, lipid synthesis, fatty acid oxidation and vitamin deficiency in cancer cells also reduced the efficiency of EGFR-targeted therapy. The agents for specific points are also shown in the figure. Abbreviations: CSC, cancer stem cell; EMT, epithelial-to-mesenchymal transition; PI3K, phosphoinositide 3-kinase; IGF-1R, insulin-like growth Factor 1 receptorCC BY · PubMed Central
Fig. 2 Extrinsic mechanisms of resistance to anti-EGFR mAbs in metastatic colorectal cancer. Tumour microenvironment plasticity confers resistance to EGFR-targeted therapy. Cetuximab and panitumumab suppress tumours through ADCC mediated by NK cells and macrophages. Dysfunction of NK cells and macrophages with lower ADCC impairs the suppression of EGFR-targeted therapy in cancer. Reduced density of effector T cells and increased PD-L1 expression in cancer cells also promote survival from cancer. CAFs promote resistance to targeted therapy by secreting growth factors that activate the RAS or MET pathway. Abnormal angiogenesis always predicts poor response to anti-EGFR mAbs. Therapies focused on the microenvironment are also shown in the figure. Abbreviations: CAFs, cancer-associated fibroblasts; NK cells, natural killer cells; ADCC, antibody-dependent cellular cytotoxicity; PD-1, programmed death 1; PD-L1, programmed death ligand 1. VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor
Fig. 2 Extrinsic mechanisms of resistance to anti-EGFR mAbs in metastatic colorectal cancer. Tumour microenvironment plasticity confers resistance to EGFR-targeted therapy. Cetuximab and panitumumab suppress tumours through ADCC mediated by NK cells and macrophages. Dysfunction of NK cells and macrophages with lower ADCC impairs the suppression of EGFR-targeted therapy in cancer. Reduced density of effector T cells and increased PD-L1 expression in cancer cells also promote survival from cancer. CAFs promote resistance to targeted therapy by secreting growth factors that activate the RAS or MET pathway. Abnormal angiogenesis always predicts poor response to anti-EGFR mAbs. Therapies focused on the microenvironment are also shown in the figure. Abbreviations: CAFs, cancer-associated fibroblasts; NK cells, natural killer cells; ADCC, antibody-dependent cellular cytotoxicity; PD-1, programmed death 1; PD-L1, programmed death ligand 1. VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptorCC BY · PubMed Central
Fig. 3 Strategies to increase anti-EGFR therapy efficiency in different subtypes of mCRC. Biomarker analysis should be conducted before treatment for mCRC. For patients with disease progression on anti-EGFR therapy, biomarker analysis is still recommended. For mCRC with driver gene alterations, there are some therapies to increase anti-EGFR efficiency. In RAS-mut mCRC, the selected therapies include a combination of RAS inhibitors and anti-EGFR agents, metabolic regulators, immune therapy, cytotoxic drugs and natural bioactive monomers. In RAF-mut mCRC, the main therapy is a BRAF inhibitor. In ERBB2-amp mCRC, ERBB2 inhibitors can be used to promote the antiproliferation of anti-EGFR. In MET-amp mCRC, combined therapy with MET inhibitors and anti-EGFR mAbs was confirmed to be effective. In mCRC with EGFR ECD-mut, new anti-EGFR agents are preferred. In mCRC with no driver gene alteration, multitargeted therapies, metabolic regulators, immune therapy, cytotoxic drugs and antiangiogenic agents can be used with anti-EGFR. Abbreviations: mCRC, metastatic colorectal cancer; EGFR, epidermal growth factor receptor; ERBB2, human epidermal growth factor receptor 2; MET, tyrosine-protein kinase Met; MSI-H, microsatellite instability; dMMR, dysfunctional mismatch repair; PD-1/PD-L1, programmed death-1/programmed death ligand 1; ECD, extracellular domain; WT, wild type; mut, mutation
Fig. 3 Strategies to increase anti-EGFR therapy efficiency in different subtypes of mCRC. Biomarker analysis should be conducted before treatment for mCRC. For patients with disease progression on anti-EGFR therapy, biomarker analysis is still recommended. For mCRC with driver gene alterations, there are some therapies to increase anti-EGFR efficiency. In RAS-mut mCRC, the selected therapies include a combination of RAS inhibitors and anti-EGFR agents, metabolic regulators, immune therapy, cytotoxic drugs and natural bioactive monomers. In RAF-mut mCRC, the main therapy is a BRAF inhibitor. In ERBB2-amp mCRC, ERBB2 inhibitors can be used to promote the antiproliferation of anti-EGFR. In MET-amp mCRC, combined therapy with MET inhibitors and anti-EGFR mAbs was confirmed to be effective. In mCRC with EGFR ECD-mut, new anti-EGFR agents are preferred. In mCRC with no driver gene alteration, multitargeted therapies, metabolic regulators, immune therapy, cytotoxic drugs and antiangiogenic agents can be used with anti-EGFR. Abbreviations: mCRC, metastatic colorectal cancer; EGFR, epidermal growth factor receptor; ERBB2, human epidermal growth factor receptor 2; MET, tyrosine-protein kinase Met; MSI-H, microsatellite instability; dMMR, dysfunctional mismatch repair; PD-1/PD-L1, programmed death-1/programmed death ligand 1; ECD, extracellular domain; WT, wild type; mut, mutationCC BY · PubMed Central

Verification

Claims the paper makes

25 Valid · 2 Not valid · 105 Not checked · 21 Own results and interpretations

106 more claims · 17 with their cited sources checked

Create a free account to see all 153 claims and to verify the 148 references still open.

See all claims — free account
  • Probably not a substantial claim. 6
  • It may state two separate claims as one. 38

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

5 of 7 · the rest aren’t loaded

2 more findings

Create a free account to see every finding of this check.

See all findings — free account

Citations

Cites

1 retracted

Show all 156 references

Cited by

See all 247

Metadata

Authors
Zhou, J., Ji, Q., & Li, Q.
Affiliations
Shanghai University of Traditional Chinese Medicine (CN)
Corresponding author
  • Ji, Qing
  • Li, Qi
Venue
Journal of Experimental & Clinical Cancer Research
Published
2021-10-18
Volume
40
Issue
1
Pages
328-328
ISSN
  • 0392-9078 (ISSN-L)
  • 1756-9966
OpenAlex
W3207379781
Cited by
246
References
156
Citations by year
2026: 53 · 2025: 71 · 2024: 60 · 2023: 38 · 2022: 24
FWCI
3.70
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Experimental & Clinical Cancer Research (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
national natural science foundation of china (81830120, 82074225)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Keywords
metastatic colorectal cancer, anti-EGFR monoclonal antibody, cetuximab, panitumumab, anti-EGFR therapy resistance, metabolic remodeling, microsatellite instability, autophagy, tumor microenvironment, cancer-associated fibroblasts, angiogenesis, immune cells, combination therapy
MeSH terms
Clinical Decision-Making, Drug Development, Animals, Antineoplastic Agents, Clinical Trials as Topic, Energy Metabolism, Gene Amplification, Humans, Ligands, Mutation, Neovascularization, Pathologic, Protein Binding, Colorectal Neoplasms, Signal Transduction, Treatment Outcome, Drug Resistance, Neoplasm, Disease Management, Protein Kinase Inhibitors, Microsatellite Instability, Molecular Targeted Therapy, Tumor Microenvironment, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies. https://app.cochat.ai/papers/10.1186/s13046-021-02130-2
The paper
Zhou, J., Ji, Q., & Li, Q. (2021). Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies. Journal of Experimental & Clinical Cancer Research. https://doi.org/10.1186/s13046-021-02130-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.